Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5993914 | 0.85 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| Acetic Acid SCHEMBL5993263 | 0.82 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3MEN1KMT2A | |
| SCHEMBL5992970 | 0.80 | GPR119 (0.46) | STSMEN1KMT2AGPR119 | |
| SCHEMBL5996682 | 0.79 | SLC6A2 (0.59) | SLC6A2SLC6A4MEN1KMT2AGPR119 | |
| SCHEMBL5993906 | 0.79 | SLC6A4 (0.51) | SLC6A2SLC6A4SLC6A3STSMEN1 | |
| SCHEMBL3267607 | 0.79 | GPR119 (0.44) | GPR119 | |
| SCHEMBL3269535 | 0.79 | GPR119 (0.44) | MEN1KMT2AGPR119 | |
| SCHEMBL5995305 | 0.78 | GPR119 (0.49) | GPR119 | |
| SCHEMBL3267888 | 0.78 | CYP3A4 (0.42) | MEN1KMT2AGPR119MAPK1 | |
| Fumaric Acid SCHEMBL5994025 | 0.76 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | ELI LILLY AND COMPANY | 2006-04-13 | — | — | US | disclosed |
| EP-1569905-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052858-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885SLC6A4 4/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.